Overview
Trusted Process
Syneos Health Inc., formerly named as INC Research Holdings, is a fully integrated biopharmaceutical solutions organization. Through the company's product development mindset, strategically blending clinical development, medical affairs and commercial capabilities, customers in the pharmaceutical, biotechnology, and healthcare industries are served. The company offers both stand-alone and integrated biopharmaceutical product development solutions
...
Read More ranging from early phase (Phase I) clinical trials to the full commercial success. Syneos' revenues mainly come from North America. The company was founded as INC Research in 1998.
Read Less
Read More ranging from early phase (Phase I) clinical trials to the full commercial success. Syneos' revenues mainly come from North America. The company was founded as INC Research in 1998.
Read Less
COSTA PANAGOS
See more contacts
Scientific Research and Development Services
,
Professional, Scientific, and Technical Services
,
Medical research, commercial
,
Biological research
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Actual
?
Actual
#
Actual
? %
? %
?
?
?
?
Contacts
Get in Touch with 5 Principals* and 4,937 Contacts
-
COSTA PANAGOSChief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of ? (12 month period) in USD
Annual Revenue 2022
?
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net Operating Cash | $427 | $450 | $425 |
| Net Investing Cash | -$106 | -$340 | -$504 |
| Net Financing Cash | -$339 | -$278 | $178 |
| Net Change in Cash | -$18 | -$168 | $100 |
| Cash at Beginning of Period | $106 | $272 | $164 |
| Cash at End of Period | $112 | $106 | $272 |
| Capital Expenditure | -$93 | -$57 | -$50 |
| Assets (mil) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $112 | $106 | $272 |
| Accounts Receivable | $899 | $873 | $775 |
| Inventories | $ | $ | $ |
| Other Current Assets | $933 | $787 | $691 |
| Asset Summary | |||
| Total Current Assets | $1,944 | $1,766 | $1,738 |
| Tangible Fixed Assets | $437 | $432 | $439 |
| Intangible Assets | $681 | $854 | $934 |
| Total Assets | $8,199 | $8,237 | $8,063 |
| Liabilities (mil) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $119 | $108 | $114 |
| Short-Term Debt | $ | $ | $ |
| Other Current Liabilities | $1,606 | $1,547 | $1,464 |
| Liability Summary | |||
| Total Current Liabilities | $1,725 | $1,654 | $1,577 |
| Long-Term Debt | $2,611 | $2,776 | $2,902 |
| Other Long-Term Liabilities | $57 | $77 | $68 |
| Total Liabilities | $4,704 | $4,825 | $4,821 |
| Stakeholder's Equity (mil) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Equity | |||
| Common Stock | $1 | $1 | $1 |
| Retained Earnings | $168 | -$13 | -$180 |
| Equity Summary | |||
| Total Equity | $3,495 | $3,413 | $3,242 |
| Shares Outstanding | 102,911,000 | 103,764,000 | 103,934,738 |